Here we are bryce having a look around might just post the progress of the Japanese patent straight from the JPO site
Translated to English....first page.
Credit to hopeful2 from the ozestock site.
Here it is:
Looks like a publication to me registration/patent to come.
(19) [Country of Issue] Japan Patent Office (JP)
(12) [Official Gazette Type] Open patent official report (A)
(11) [Publication No.] JP,2003-96096,A (P2003-96096A)
(43) [Date of Publication] April 3, Heisei 15 (2003. 4.3)
(54) [Title of the Invention] Tumor necrosis factor joint ligand.
(51) [The 7th edition of International Patent Classification]
C07K 14/47 ZNA . A61K 45/00 . A61P 35/00 . 35/02 . //C07K 16/24 ZTD . C12P 21/08 .
[FI]
C07K 14/47 ZNA . A61K 45/00 . A61P 35/00 . 35/02 . C07K 16/24 ZTD . C12P 21/08 .
[Request for Examination] ****
[The number of claims] 31.
[Mode of Application] OL.
[Number of Pages] 29.
(21) [Filing Number] Application for patent 2002-234004 (P2002-234004)
(62) [Divisional Application] Division of Japanese Patent Application No. 2-510780.
(22) [Filing Date] August 7, Heisei 2 (1990. 8.7)
(31) [Priority Document Number] PJ5662.
(32) [Priority Date] August 7, Heisei 1 (1989. 8.7)
(33) [Country Declaring Priority] Australia (AU)
(31) [Priority Document Number] PJ7576.
(32) [Priority Date] November 24, Heisei 1 (1989. 11.24)
(33) [Country Declaring Priority] Australia (AU)
(71) [Applicant]
[Identification Number] 500468537.
[Name] PEPUTEKKU Limited.
[Address] Australia Nu South Wales 2113 North RAIDO Waterloo Loading 35-41.
(72) [Inventor(s)]
[Name] Deborah Ann lath JIEN.
[Address] Australia country 2120 ENUESU W Sone lei EDDI Street 4.
(72) [Inventor(s)]
[Name] Roger Aston.
[Address] Australia country 2120 ENUESU W Waist Pennant HIRUZU Highness Loading 2430 Lot.
(74) [Attorney]
[Identification Number] 100064908.
[Patent Attorney]
[Name] Shiga Masatake (besides one person)
[Theme code (reference)]
Four B064. 4C084. 4H045.
[F term (reference)]
4B064 AG27 CA19 CA20 DA01. 4C084 AA17 NA14 ZB262 ZB272. 4H045 AA10 AA30 bus-available10 EA20 FA33 FA58 FA59 FA61 GA25.
--------------------------------------------------------------------------------
[Translation done.]
* NOTICES *
Japan Patent Office is not responsible for any damages caused by the use of this translation.
1. This document has been translated by computer.So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3.In the drawings, any words are not translated.
(57) [Abstract]
[Technical problem] The antibody which checks alternatively the activity from which TNF alpha differs, or promotes it.
[Means for Solution] They are ligands, such as a specific monoclonal antibody, to the TOPOGURAFIKKU field where TNF alpha differs. If these ligands are combined with TNF, neoplasm degradation, guidance of an inner-bark procoagulant, guidance of neoplasm fibrin deposition, cytotoxicity, and the activity of acceptor combination will be influenced alternatively. As a desirable example of a ligand, an antibody, F (ab) fragment, a reconstruction antibody (CDR transplant hominization antibody) single domain antibody (dAbs), a single chain antibody, blood serum binding protein, an acceptor, etc. are mentioned.
